Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Wriggleson Nov 02, 2021 12:00am
650 Views
Post# 34075885

RE:Timeline

RE:Timeline
Not much new here on schedule from what was said in the Echelon report October 19.
 
https://www.cantechletter.com/2021/10/antibe-therapeutics-has-a-159-per-cent-upside-says-echelon/#    
"Moving forward, Quenneville notes that the company’s plan for otenaproxesul is to quickly undertake a Phase I study to establish dosing parameters for a loading dose regimen and to determine the speed of the drug’s analgesic onset, with an intent to move to a Phase II study likely in bunionectomy surgery patients, which is the most typical population used in trials for post-operative pain drugs, with Quenneville noting that the trial could be initiated in the second half of 2022, with results coming within six to 12 months.
 
From there, a potential Phase III study for otenaproxesul would likely entail a larger bunionectomy trial and a trial in soft-tissue surgery patients, which usually involves abdominoplasty (“tummy tuck”) or cosmetic breast surgery patients. Quenneville notes that the studies can be done simultaneously, with results potentially available within 12 to 18 months, meaning a significantly shorter than the company’s previously anticipated osteoarthritis trials."
 
<< Previous
Bullboard Posts
Next >>